Compare Abbott Laboratories (ABT) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Wheaton Precious Metals Corp — how do they compare? Abbott Laboratories trades at $95.55 (market cap $166.94B), while Wheaton Precious Metals Corp trades at $107.37 (market cap $50.76B). The key difference: Abbott Laboratories is far larger — about 3.3× Wheaton Precious Metals Corp's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | WPM | |
|---|---|---|
Market Cap | $166.94B | $50.76B |
Sector | Health | Basic Materials |
52-Week High | $136.62 | $165.72 |
52-Week Low | $82.57 | $86.72 |
Enterprise Value | $193.69B | $48.61B |
Dividend Yield | 2.63% | 0.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Wheaton Precious Metals (WPM) trades at $111.89, down 3.32% recently amid broader precious metals volatility. The stock shows strong fundamentals with record 2025 revenue of $2.31B and net income of $1.47B, supported by three consecutive quarterly EPS beats. Technical indicators signal bearish momentum with key support at $109, while analyst consensus remains strongly bullish with an $169 price target representing 51% upside potential from current levels.
WPM presents a compelling growth story with exceptional profitability margins (65.55% net income margin) and projected 2026 revenue growth to $2.7B. Primary risks include precious metal price volatility and geopolitical tensions affecting mining operations. The 80% buy rating from analysts suggests significant upside potential despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
